title: Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer.
abstract: OBJECTIVE
  Currently available therapies do improve survival in advanced stage non-small cell lung cancer (NSCLC), but only to a limited degree. Talabostat mesilate (PT-100) is an orally available amino boronic dipeptide that specifically inhibits dipeptidyl peptidases (including fibroblast activation protein) and enhances an immune response. The aim of this study was to determine the efficacy and safety of talabostat in NSCLC patients.
  
  
  METHODS
  A phase II trial was conducted to evaluate talabostat in combination with docetaxel in patients with advanced NSCLC after failure of previous platinum-based chemotherapy. In total, 42 patients were enrolled.
  
  
  RESULTS
  Talabostat was well tolerated. Two patients achieved a partial response and one achieved a complete response.
  
  
  CONCLUSIONS
  There was no evidence that talabostat enhanced the clinical activity of docetaxel in patients with NSCLC.
authors.affiliation: Mary Crowley Cancer Research Centers, Dallas, Texas, USA.
authors.forename: R M
authors.initials: RM
authors.lastname: Eager
authors.forename: C C
authors.initials: CC
authors.lastname: Cunningham
authors.forename: N
authors.initials: N
authors.lastname: Senzer
authors.forename: D A
authors.initials: DA
authors.lastname: Richards
authors.forename: R N
authors.initials: RN
authors.lastname: Raju
authors.forename: B
authors.initials: B
authors.lastname: Jones
authors.forename: M
authors.initials: M
authors.lastname: Uprichard
authors.forename: J
authors.initials: J
authors.lastname: Nemunaitis
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D004151:Dipeptides / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D001897:Boronic Acids; D004151:Dipeptides; D043823:Taxoids; D000077143:Docetaxel; C514044:talabostat